Shelter Pharma launches SHELTIDIN DS herbal cough spray for domestic market

1 min read | Published on 21 Aug 2026, 12:35 PM |Updated on 21 Aug 2026, 12:35 PM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Shelter Pharma launched SHELTIDIN DS, an herbal cough spray, on August 20, 2026
The product addresses dry cough, sore throat, and hoarseness via spray delivery
Initial distribution is through e-commerce platforms targeting the domestic market
The company may explore international expansion for this product in the future

*this image is generated using AI for illustrative purposes only.

Shelter Pharma Ltd launched SHELTIDIN DS, a new herbal human healthcare product, on August 20, 2026. The cough spray targets dry and irritating coughs, sore throats, and hoarseness of voice.

The company disclosed the launch under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The product is currently available on reputed e-commerce platforms.

Product Details

SHELTIDIN DS is formulated by the company's in-house research and development team. It uses a spray-based delivery format designed to provide direct soothing comfort to the throat. The formulation aims to offer fast and effective relief from everyday throat discomfort.

Particulars	Details
Product Name	SHELTIDIN DS
Launch Date	August 20, 2026
Category	Herbal Human Healthcare
Market Focus	Domestic

Strategic Context

Shelter Pharma has operated in the pharmaceutical and healthcare industry for over 60 years. The company states that its manufacturing facilities comply with Good Manufacturing Practices approved by the FDA and relevant ISO standards.

While the initial launch focuses on the domestic market, the company indicated it may explore international opportunities in due course. This addition to the portfolio supports the firm's long-term growth strategy and commitment to innovation.

Historical Stock Returns for Shelter Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.62%	-1.79%	+18.50%	-8.82%	0.0%	0.0%

How does the launch of SHELTIDIN DS align with Shelter Pharma's broader strategy to diversify beyond its traditional pharmaceutical offerings?

What are the projected sales targets for SHELTIDIN DS in its first year, and how might this impact Shelter Pharma's overall revenue growth?

Given the competitive landscape of herbal healthcare products, what specific marketing strategies will Shelter Pharma employ to differentiate SHELTIDIN DS on e-commerce platforms?

Shelter Pharma

View Company Insights

View All News

Shelter Pharma appoints Dr. Vinita Gadhvi as independent director for five years

1 min read | Published on 31 Jul 2026, 11:36 AM |Updated on 31 Jul 2026, 11:43 AM

Reviewed by

Riya DScanX News Team

Add as a preferred
source on Google

Key Highlights

Shelter Pharma Limited has appointed Dr. Vinita Shivraj Gadhvi as an Additional Non-Executive Independent Director for a fixed tenure of five years, effective July 31, 2026. The appointment was approved by the Board following a recommendation from the Nomination and Remuneration Committee and is subject to shareholder approval. Dr. Gadhvi brings over 12 years of experience in pharmaceuticals and healthcare innovation. Consequently, the Corporate Social Responsibility Committee was reconstituted to include her as a member.

*this image is generated using AI for illustrative purposes only.

Shelter Pharma Limited appointed Dr. Vinita Shivraj Gadhvi as an Additional Non-Executive Independent Director on July 31, 2026, strengthening its Board composition with a healthcare professional holding a Ph.D. and over 12 years of industry experience. The appointment, made pursuant to Sections 149, 152, and 161(1) of the Companies Act, 2013, carries a fixed tenure of five consecutive years, during which she will not be liable to retire by rotation, pending final shareholder approval at the next Annual General Meeting.

The Board of Directors approved the appointment following a recommendation from the Nomination and Remuneration Committee. Dr. Gadhvi holds office as an Additional Director until the date of the next Annual General Meeting. The company confirmed that she satisfies all statutory criteria for independence under Section 149(6) of the Companies Act, 2013, and is not related to any existing Director or Key Managerial Personnel. Furthermore, she is not debarred from holding office by SEBI or any other authority.

Reconstitution of CSR Committee

Consequent to the change in Board composition, Shelter Pharma reconstituted its Corporate Social Responsibility (CSR) Committee effective July 31, 2026, in compliance with Section 135 of the Companies Act, 2013. Dr. Gadhvi joins the committee as a member, while Mr. Mosinkhan Gafarkhan Pathan continues as Chairman.

DIN	Name	Designation	Position in Committee
10039962	Mosinkhan Gafarkhan Pathan	Non-Executive Independent Director	Chairman
09102407	Vinita Shivraj Gadhvi	Non-Executive Independent Director	Member
01456841	Mustaqim Nisarahmed Sabugar	Managing Director	Member
01470286	Parvezbanu Mohamed Rafiq Idariya	Director	Member

What the Numbers Show

The appointment highlights a strategic focus on integrating deep domain expertise into governance structures. Dr. Gadhvi’s background includes an MBA in Total Quality Management and a Ph.D. focused on the Indian Healthcare Startup Ecosystem. Her professional recognition includes innovation grants from SSIP, GUSEC, and i-Hub Gujarat, along with features in government publications such as Women in Startups. This profile suggests an emphasis on quality assurance, regulatory compliance, and strategic business development within the company’s oversight framework.

The Board meeting commenced at 10:45 A.M. and concluded at 11:15 A.M. on July 31, 2026, in Ahmedabad. The disclosure was made under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Master Circular No. HO/49/14/14(7)2025-CFD-POD2/I/3762/2026 dated January 30, 2026.

Historical Stock Returns for Shelter Pharma

1 Day	5 Days	1 Month	6 Months	1 Year	5 Years
+0.62%	-1.79%	+18.50%	-8.82%	0.0%	0.0%

How might Dr. Gadhvi's expertise in the Indian Healthcare Startup Ecosystem influence Shelter Pharma's future R&D strategy or potential M&A targets?

What specific CSR initiatives is the reconstituted committee likely to prioritize given Dr. Gadhvi's background in quality management and innovation?

Could the addition of an independent director with a Ph.D. signal a shift towards more rigorous regulatory compliance or quality assurance standards for the company's products?

Shelter Pharma

View Company Insights

View All News